cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1737Research ArticleПРЕСС-РЕЛИЗПРЕСС-РЕЛИЗИсследование BEAUTIFUL - шаг вперед на пути дальнейшего снижения риска сердечно-сосудистых событий у пациентов с ишемической болезнью сердцаРедакционнаястатья20082012200878112113Copyright © Редакционная с., 20082008Редакционная с.Редакционная с.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1737
.
ReferencesProjections of Global Mortality and Burden of Disease from 2002 to 2030 PLoS Med 3(11): e442. pmed.0030442 DOI: 10.1371/journalProjections of Global Mortality and Burden of Disease from 2002 to 2030 PLoS Med 3(11): e442. pmed.0030442 DOI: 10.1371/journalDiaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Fox K, Borer JS, Camm AJ, et al. Resting Heart Rate in Cardiovascular Disease. JACC 2007; 50: 823-30.Fox K, Borer JS, Camm AJ, et al. Resting Heart Rate in Cardiovascular Disease. JACC 2007; 50: 823-30.Fox K, Ferrari R, Tendera M, et al. Rationale and desing of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morbidity-mortality evaluation of If-inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) Study. Am Heart J 2006; 152: 860-6Fox K, Ferrari R, Tendera M, et al. Rationale and desing of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morbidity-mortality evaluation of If-inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) Study. Am Heart J 2006; 152: 860-6BEAUTIFUL Study Group. The BEAUTIFUL Study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction -baseline characteristics of the study population. Cardiology 2008; 110: 271-82.BEAUTIFUL Study Group. The BEAUTIFUL Study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction -baseline characteristics of the study population. Cardiology 2008; 110: 271-82.Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203-12.Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203-12.Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective Irinhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective Irinhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16.Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16.
The authors declare that there are no conflicts of interest present.